Familial Dysautonomia (ELP1/IKBKAP): What a 23andMe Ashkenazi Carrier Result Really Means, and the First 2024 Splice-Correcting Therapy

Familial Dysautonomia (ELP1/IKBKAP): What a 23andMe Ashkenazi Carrier Result Really Means, and the First 2024 Splice-Correcting Therapy

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Two 2001 gene-discovery papers pinned familial dysautonomia (FD) to a single founder change in the ELP1 gene, once named IKBKAP. Read alongside GeneReviews and NIH, the science is reassuring. A 23andMe carrier line is not a diagnosis. FD is autosomal recessive, so a carrier is healthy. Risk to a future child rises only if both partners carry the variant. And in 2024, a splice-correcting therapy entered the clinic for the first time, though it remains investigational and unapproved.

What you’ll learn:

• Why an inherited “carrier” result on a home test is different from having the disease itself
• The exact absolute-risk numbers for a future child, and why partner testing is the pivotal next step
• What the 2001 gene-discovery research and the 2024 splice-correcting therapy actually mean for families today
• How genetic results affect insurance in the United States and Canada, and where the legal gaps are

Genetic terms can feel frightening at midnight. This guide translates the research into plain English. It follows the decision path a worried, family-planning reader of Ashkenazi descent actually walks, from a home-test carrier line to the genetic counselor’s office.

1. How Familial Dysautonomia Is Inherited: The ELP1 Gene

Familial dysautonomia is caused by changes in a single gene called ELP1, which was formerly named IKBKAP and sits on chromosome 9. That gene carries instructions for a protein called ELP1, also known as IKAP. Think of ELP1 as one part of a six-piece tool called the Elongator complex.

The Elongator complex helps cells read their genes and fine-tune tiny carrier molecules called transfer RNA. When ELP1 is in short supply, developing nerve cells suffer the most. That is why FD damages the sensory nerves, which carry sensations like pain and temperature, and the autonomic nerves, which quietly run blood pressure, digestion, and tears.

Nearly all cases trace to one specific change. The 2001 gene-discovery papers found a founder splice variant, written c.2204+6T>C, that weakens a splicing signal. That weak signal makes the cell skip a piece of the gene called exon 20. This skipping happens in a tissue-specific way, hitting the nervous system hardest, which lowers the amount of working protein there. A companion 2001 paper independently confirmed the same gene and variant, showing that FD cells make a shortened, non-working protein because the RNA is missing exon 20.

A helpful way to picture “tissue-specific skipping” is a printer that drops one page only on certain jobs. In many tissues, cells still make a good share of full-length protein, but nerve cells make far less. That is why the damage concentrates in the nervous system rather than the whole body. Crucially for later sections, this exon-20 skipping is the exact defect that experimental splice-correcting therapies aim to reverse.

There is a second, much rarer FD change worth naming for completeness. A minor haplotype carries a missense variant in exon 19, which alters a single building block of the protein rather than skipping a whole piece. It accounts for only a small fraction of cases. For a 23andMe-primed reader, the practical point is simpler. The home test looks for the common founder splice variant. That variant is the one behind more than 99% of disease alleles in Ashkenazi families.

FD follows an autosomal recessive pattern, meaning a child must inherit one non-working ELP1 copy from each parent to be affected. Every person has two copies of the gene. If only one copy is changed, the working copy covers the job, and that person is a healthy carrier. This is the single most important idea for a worried reader to hold onto: a carrier is not sick.

Why is FD so closely tied to Ashkenazi Jewish families? Genomic references note that more than 99% of disease alleles in this population carry the same founder variant. That change arose long ago in a small founder population and spread quietly across generations. Because almost everyone affected shares this one variant, a targeted test for it is highly informative in Ashkenazi couples.

Here is the arithmetic that answers most families’ fears. When both parents are healthy carriers, each pregnancy carries a fixed set of odds, like flipping two coins:

Outcome per pregnancy	Chance
Affected child (two changed copies)	25% (about 1 in 4)
Healthy carrier child (one changed copy)	50% (about 1 in 2)
Unaffected child (two working copies)	25% (about 1 in 4)

Importantly, these odds reset with every pregnancy. One outcome does not “use up” the risk or protect the next. A genetic counselor can walk you through these numbers for your own family. You can find one through the National Society of Genetic Counselors at NSGC.org.

Section recap: FD comes from inheriting a changed ELP1 copy from both parents; a single changed copy makes you a healthy carrier, and two carrier parents face a 25% chance of an affected child per pregnancy.

2. How Common Is It, and Does a Carrier Result Mean Sickness?

Numbers calm the mind better than vague warnings, so here are the real ones for a reader of Ashkenazi descent:

• Carriers (healthy, one changed copy): GeneReviews reports a founder-variant carrier frequency of about 1 in 32 among Ashkenazi Jews. A natural-history review cites a similar rate of roughly 1 in 32. In other populations, the variant is rare to nearly absent.
• Affected (the disease itself): NIH estimates FD affects roughly 1 in 3,700 people of Ashkenazi Jewish descent.

So being flagged as a carrier puts you in a common group of healthy people, not a rare and sick minority. Roughly 3 out of every 100 Ashkenazi Jewish adults carry this variant and are perfectly healthy.

A carrier is healthy. That deserves repeating, because a home-test report can make “carrier” sound like a verdict. The word means only that you carry one changed copy that you could pass to a child. It has nothing to do with whether you feel well. Carrier status matters for reproductive planning, not for your own daily health.

For a person who is affected, the picture is very different and begins in infancy. When someone inherits two changed copies, the founder variant is considered essentially fully penetrant, meaning the condition shows up rather than staying hidden. Clinical signs include alacrima (an absence of overflow tears) and absent fungiform tongue papillae (missing small bumps on the tongue). They also include reduced reflexes and autonomic crises, with swings in blood pressure and cyclic vomiting.

It also helps to know the outlook has improved. FD was historically defined by early mortality. Under modern supportive care at specialized centers, survival has improved markedly, and many patients now reach adulthood. Severity and lifespan still vary from person to person. None of this applies to a healthy carrier; it describes only someone with two changed copies, confirmed by a specialist.

Section recap: The founder variant is common in Ashkenazi Jews (about 1 in 32 carriers), while the disease is rare (about 1 in 3,700); a carrier result signals reproductive relevance only, and true FD begins in infancy with survival now much improved under modern care.

3. Testing Options: Home Kit Versus the Clinical Pathway

There are two very different worlds of genetic testing, and confusing them causes needless panic. A home kit can start a conversation, but only the clinical pathway confirms a diagnosis. Here is how the two compare:

Feature	Home kit (DTC)	Clinical pathway
Example	23andMe carrier report	Carrier screening or ELP1 testing ordered by a clinician
Purpose	Risk of passing a condition to a child; not for diagnosis	Reproductive screening, or confirming a diagnosis
Variants checked	One founder variant only	Founder panel or broader gene sequencing
Ordered by	The consumer	An OB-GYN or genetic counselor, run at a certified lab

Start with what a home kit actually is. In 2015, the FDA granted 23andMe the first authorization to sell carrier-status reports, later expanding to more than 40 conditions including familial dysautonomia. That authorization is explicit on two points. Carrier reports convey the risk of passing a condition to a child and are not intended to diagnose disease. And the FD report tests only the single Ashkenazi founder variant, so a “variant not detected” result does not rule out rarer non-founder changes.

For reproductive planning, the standard clinical route runs through an OB-GYN or a genetic counselor. They can order a targeted Ashkenazi Jewish carrier panel, which includes the ELP1 founder variant, or a broader expanded carrier screen. A professional guideline now recommends offering expanded carrier screening to all patients who are pregnant or planning pregnancy, regardless of ethnicity. These tests run at certified laboratories such as Invitae, Natera, or Myriad, or through the community program Dor Yeshorim.

Diagnosing a symptomatic infant follows a different path. That runs through a pediatric neurology or genetics evaluation, combining ELP1 molecular testing with recognition of the clinical signs, such as absent overflow tears and missing tongue papillae. FD is not part of standard U.S. newborn screening, so it is found clinically or through targeted testing, not caught automatically at birth. If a baby shows these signs, do not wait for a screening program. Raise it directly with a pediatrician or a genetic counselor at NSGC.org.

Section recap: A 23andMe report reads only the single founder variant and is a carrier screen, not a diagnosis; clinical carrier screening through an OB-GYN or counselor is the right reproductive route, and an affected infant needs a specialist evaluation with ELP1 testing.

4. Reading Your Results: Carrier, Affected, or Uncertain

A genetic report can return several different answers, and knowing the vocabulary keeps a family grounded. There are three main results, and each carries a very different meaning:

• Carrier status — one changed ELP1 copy, almost always the founder variant; the person is healthy, and the finding matters only for reproductive planning. A 23andMe carrier line points to one detected variant, not disease. Risk to a child rises only when both partners are carriers.
• Affected diagnosis — two changed copies confirmed, with the characteristic sensory and autonomic features verified by a specialist. Only a physician plus a genetic counselor can integrate genotype, family history, and symptoms into this call.
• Variant of uncertain significance (VUS) — a change whose effect is not yet known. This is uncommon for FD, because testing usually targets the single well-characterized founder variant, but it can appear on broad sequencing panels. ACMG/AMP standards sort variants into five tiers, from clearly harmful to clearly harmless, and a VUS can be reclassified later as evidence accumulates.

The single most important message is this: a carrier line means one detected founder variant, not disease. The situation that actually raises a future child’s risk is two carriers in a couple, which is precisely why partner testing is the decisive next step. Self-interpreting a home report, in either direction, is exactly what a counseling visit is designed to prevent. False reassurance and unnecessary panic are both avoidable. A genetic counselor can help interpret any result; find one at NSGC.org.

Section recap: Results come as healthy carrier status, an affected diagnosis, or an uncertain variant; a carrier line is not a diagnosis, and only two carriers in a couple raise a child’s risk, so partner testing plus a counselor’s interpretation is the grounded next step.

5. Prevention and Management: Two Levels of Care

For FD, “prevention” operates on two levels, and both are grounded in the research. Neither is a do-it-yourself project, which is one more reason to work with a genetic counselor at NSGC.org.

The first level is reproductive planning. Familial dysautonomia cannot be prevented once a child inherits two changed copies, so the planning happens beforehand. A couple who are both carriers can discuss options with a genetic counselor. These options include prenatal diagnosis and preimplantation genetic testing for monogenic disease, known as PGT-M, during fertility treatment. Community screening programs such as Dor Yeshorim have long helped Ashkenazi couples learn their carrier status before starting a family.

It helps to know what each option actually involves, in plain terms. Prenatal diagnosis tests a current pregnancy, usually through chorionic villus sampling or amniocentesis, to learn whether the baby inherited both changed copies. PGT-M works earlier: during in vitro fertilization, embryos are tested for the founder variant before one is transferred, so a couple can choose an embryo that would not be affected. Because the founder variant is a single, well-defined change, both approaches are technically straightforward once a couple’s carrier status is known. None of these is a decision to make alone or in a hurry. A counselor’s job is to lay out the trade-offs, costs, and emotional weight of each path so a couple can choose what fits their values.

The second level is disease management for someone who is affected. Here, care is supportive management coordinated by many specialists at once, through centers such as the NYU Dysautonomia Center. Because the autonomic nerves misfire, day-to-day care focuses on a few recurring risks:

• Protecting the airway and preventing aspiration, since swallowing can be unsafe
• Managing autonomic crises, including blood-pressure swings and cyclic vomiting
• Using artificial tears for alacrima, since the eyes do not make overflow tears
• Providing feeding support and monitoring the spine and orthopedic health

Think of supportive care as steady scaffolding around a building whose wiring runs unevenly. It does not rewire the system, but it keeps the structure safe and functioning. Under this modern, center-based care, survival has improved markedly compared with historical outcomes.

Because there is no newborn screen, the real “early detection” is prompt recognition of the classic infant signs, followed by referral to a specialist center. A parent who notices absent tears, missing tongue papillae, or feeding trouble should raise it with a pediatrician quickly rather than waiting. Early referral is the practical step that most improves outcomes.

Section recap: Prevention happens before pregnancy through carrier-aware planning, prenatal testing, PGT-M, and community screening, while an affected person needs lifelong, center-based supportive care that has markedly improved survival.

6. The Latest Treatment and Research Landscape

Families understandably scan headlines for a cure, so let this section be direct. As of 2026, there is no disease-modifying drug, gene therapy, or splice-correcting medicine approved by the FDA or Health Canada specifically for familial dysautonomia. Approved care remains supportive. Yet the research picture is genuinely more hopeful than the disease’s grim history, so readers deserve to be neither misled nor left hopeless.

The lead story is splice modulation. Because the founder variant causes exon-20 skipping, therapies that restore exon-20 inclusion target the root defect rather than just the symptoms. An antisense oligonucleotide, a short piece of genetic material delivered into the spinal fluid, was developed in the Krainer laboratory at Cold Spring Harbor Laboratory. It binds the gene’s pre-mRNA to promote exon-20 inclusion and the production of full-length, working ELP1 protein in neurons.

This therapy is worth understanding precisely because of its limits. It was advanced as an individualized, or N-of-1, investigational therapy through the nonprofit n-Lorem Foundation. It entered the clinic with early reported progress in its first treated patient in 2024. It is investigational and not approved by the FDA or Health Canada, and eligibility for such N-of-1 programs is narrow and specialist-directed. Early progress in one patient is a beginning, not a proven treatment.

Two other lines of work support the same strategy but remain research-stage:

• Kinetin, a plant compound, was shown in 2004 to sharply increase exon-20 inclusion and push working protein back toward normal levels in cultured FD cells. This was the first proof of concept that a small molecule could correct the splicing defect, but kinetin is not an approved drug.
• BPN-15477, a small-molecule splicing modulator from the Krainer laboratory, was reported in 2021 to restore exon-20 inclusion and raise full-length protein in patient-derived cells and in a humanized mouse model. It too is research-stage, not an approved medicine.

Notice a common thread across all three efforts: kinetin, BPN-15477, and the antisense oligonucleotide each target the same exon-20 skipping identified back in 2001. In other words, the decades-old discovery of the founder variant handed researchers a precise target, and today’s experimental therapies are attempts to hit it. A natural-history review notes that formal trials of symptomatic treatments have been run while splicing-modification therapies advanced in development. That is why the field frames FD as a disease with a plausible molecular target rather than a hopeless one.

Two honest cautions belong alongside the hope. First, results in cells and mice do not guarantee benefit or safety in people, which is exactly what clinical testing must establish. Second, N-of-1 programs are designed around a single patient’s biology, so access is narrow and specialist-directed. Long-term outcome data under modern supportive care, and the classification of rare non-founder ELP1 variants, are also still accumulating.

Taken together, this research means FD has moved from an untreatable disease to one with a plausible molecular target. That is a real and honest reason for hope. But every one of these approaches is investigational, and none changes the standard of care today, which stays multidisciplinary and supportive. For your own situation, a specialist and a genetic counselor at NSGC.org can explain how current evidence applies.

Section recap: No drug, gene therapy, or splice-correcting medicine is FDA- or Health Canada-approved for FD as of 2026; the promising splice-correcting antisense therapy and the kinetin- and BPN-15477-class compounds are all investigational, and care remains supportive.

7. What It Means for the Whole Family: Cascade Testing

A carrier or affected result sends ripples through a family tree, especially in Ashkenazi families where the founder variant is common. When a child is affected, both parents are automatically carriers, because each supplied one changed copy. That single fact reshapes what relatives may want to consider. It turns a private result into a family matter.

The main tool here is cascade testing, which means offering targeted founder-variant testing outward from the person who tested positive. Because the test looks for one well-characterized variant, it is straightforward to offer to relatives. Who to consider, and why:

• Siblings of a carrier — each has roughly a 50% chance of also carrying the founder variant. Knowing early lets them plan before or during their own pregnancies.
• Cousins and other Ashkenazi-descent relatives — may want testing for their own reproductive planning.
• A carrier’s partner — the pivotal test, since a child’s risk rises only if both partners carry the variant.

For a couple where both are carriers, a genetic counselor can lay out the full menu of reproductive options. These may include natural conception with prenatal diagnosis, PGT-M with IVF, donor gametes, or proceeding with informed monitoring. Neither testing nor any single path is a decision to rush; each deserves a careful counseling conversation. The counselor’s role is to explain choices, not to push any one path.

There is a human side to cascade testing worth naming. Reaching out to relatives about a genetic result can feel awkward, and some family members may not want to know. No one is obligated to test, and the information is shared as an offer, not a demand. A genetic counselor can help frame that conversation and respect each person’s choice.

The practical next step is to reach the right professionals. In the United States, families can locate a board-certified genetic counselor through the NSGC “Find a Genetic Counselor” tool at NSGC.org. In Canada, provincial genetics clinics provide the same service. Well-established Ashkenazi community programs such as Dor Yeshorim and JScreen also offer low-cost partner and relative testing.

Section recap: Because the founder variant is common in Ashkenazi families, a positive result makes cascade testing valuable; a carrier’s siblings each face about a 50% carrier chance, and a counselor plus community programs like Dor Yeshorim can coordinate partner and relative testing.

8. Insurance, Privacy, and the Emotional Weight in the US and Canada

Behind the genetics sit real-world worries about insurance, jobs, and family disclosure. The good news is that laws in both countries offer meaningful protection, though with important limits. Here is where each protection starts and stops:

Protection	United States (GINA, 2008)	Canada (GNDA, 2017)
Health insurance	Protected	Protected
Employment	Protected	Protected
Life / disability / long-term-care insurance	Not covered by GINA	Covered — broader reach
Legal status	Federal law; some states add more	Upheld by Supreme Court, 2020 (5-4)

In the United States, the Genetic Information Nondiscrimination Act, or GINA, passed in 2008, is the central shield. It bars health insurers and employers from using genetic information to discriminate. The Affordable Care Act separately bans exclusions for pre-existing conditions in health coverage. So a carrier result should not cost you your health plan or your job.

There is one gap every family should understand before buying policies. GINA does not cover life insurance, disability insurance, or long-term-care insurance. Some U.S. states have added broader protections that reach these lines, so local rules matter. A useful mental model helps: GINA is strong where it applies, but its walls do not enclose the whole yard. The exposed corners are exactly the policies families often buy when starting a family. This is a practical reason to weigh such policies thoughtfully and to ask a professional before disclosing results.

Canada offers broader federal protection. The Genetic Non-Discrimination Act became law in 2017, and in 2020 the Supreme Court of Canada upheld its key provisions in a 5-4 decision. The Act makes it illegal to require someone to take or disclose a genetic test as a condition of a service or contract, including insurance. That reaches further than U.S. GINA, which is limited to health insurance and employment.

Coverage for care differs by system. In the U.S., carrier screening and specialist care are generally covered by ACA or Medicaid plans, though coverage of PGT-M and IVF varies widely by state and plan. In Canada, provincial health plans such as OHIP and RAMQ cover much of this care, with PGT-M and IVF coverage also varying. Finally, it is normal to feel shaken by a “Jewish genetic disease” carrier line while planning a family. Yet the steadying message from the evidence is clear: a carrier is healthy, and an informed partner test usually resolves the central worry. A genetic counselor at NSGC.org can help you weigh insurance timing and the emotional side together.

Section recap: U.S. GINA and the ACA protect health insurance and jobs but leave life, disability, and long-term-care insurance exposed, while Canada’s 2017 law (upheld in 2020) protects more broadly; carrier status carries no health consequence, and a partner test usually resolves the core worry.

Frequently Asked Questions

1. My 23andMe report says I’m a carrier for familial dysautonomia — does that mean I have it or will get sick? No. A carrier line means you carry one changed ELP1 copy, not two, and carriers are healthy. FDA authorization states these reports are not intended to diagnose disease. It matters for family planning, not your own daily health. Discuss it with a genetic counselor at NSGC.org.

2. What are the chances my future child would actually have familial dysautonomia? It depends entirely on whether your partner is also a carrier. If both parents carry the founder variant, each pregnancy carries a 25% chance of an affected child. If your partner tests negative for the founder variant, the practical risk is very low. A counselor can give you exact numbers.

3. Does my fiancé need to get tested before we try for a baby? Yes, partner testing is the pivotal step. A child’s risk rises only when both partners carry the variant. Your OB-GYN or a genetic counselor can order carrier screening, and Ashkenazi community programs such as Dor Yeshorim also offer it.

4. Is there any treatment or cure for familial dysautonomia yet? As of 2026, no disease-modifying drug, gene therapy, or splice-correcting medicine is FDA- or Health Canada-approved for FD. A splice-correcting antisense therapy entered the clinic in 2024, but it is investigational and not approved. Care remains multidisciplinary and supportive.

5. Will a genetic result affect my insurance, and should I get a second opinion? In the U.S., GINA protects health insurance and jobs but not life, disability, or long-term-care insurance. Canada’s 2017 law offers broader protection. A second opinion from a specialist and a genetic counselor at NSGC.org is always reasonable for a genetic result.

Summary

A carrier line on a home genetic test is a starting point for a conversation, not a diagnosis. Familial dysautonomia is a rare, autosomal recessive condition in which a shortage of the ELP1 protein damages sensory and autonomic nerves. In Ashkenazi Jewish families, more than 99% of cases trace to one founder variant. About 1 in 32 people carry that variant while remaining perfectly healthy.

Because FD is recessive, a carrier is healthy. Risk to a future child rises only when both partners are carriers, which is why partner testing is the single pivotal next step. The strongest recent news is genuinely hopeful. A splice-correcting antisense therapy targeting the root exon-20 defect entered the clinic in 2024, though it is investigational and not FDA- or Health Canada-approved. Care today remains supportive and center-based, with markedly improved survival. Cascade testing helps the wider family, and laws in the U.S. and Canada protect against many, though not all, forms of insurance discrimination. The single best next step is a conversation with an OB-GYN and a board-certified genetic counselor, who can turn these general facts into a plan for your family.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. (2001). Tissue-Specific Expression of a Splicing Mutation in the IKBKAP Gene Causes Familial Dysautonomia. Am J Hum Genet 68(3):598-605. https://pubmed.ncbi.nlm.nih.gov/11179008/
2. Anderson SL, Coli R, Daly IW, et al. (2001). Familial Dysautonomia Is Caused by Mutations of the IKAP Gene. Am J Hum Genet 68(3):753-758. https://pubmed.ncbi.nlm.nih.gov/11179021/
3. Gold-von Simson G, Axelrod FB, et al. Familial Dysautonomia. GeneReviews (NCBI Bookshelf, NBK1180). https://www.ncbi.nlm.nih.gov/books/NBK1180/
4. NIH MedlinePlus Genetics. Familial dysautonomia. https://medlineplus.gov/genetics/condition/familial-dysautonomia/
5. NIH MedlinePlus Genetics. ELP1 gene (formerly IKBKAP). https://medlineplus.gov/genetics/gene/elp1/
6. OMIM #223900. Dysautonomia, Familial; FD. https://omim.org/entry/223900
7. Norcliffe-Kaufmann L, Slaugenhaupt SA, Kaufmann H (2017). Familial dysautonomia: History, genotype, phenotype and translational research. Prog Neurobiol 152:131-148. https://pubmed.ncbi.nlm.nih.gov/27317387/
8. FDA (2015). De Novo authorization DEN140044 — 23andMe Personal Genome Service Carrier Status reports. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN140044.pdf
9. Slaugenhaupt SA, Mull J, Leyne M, et al. (2004). Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 13(4):429-436. https://pubmed.ncbi.nlm.nih.gov/14709595/
10. Sinha R, Kim YJ, Nomakuchi T, et al. (2021). Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia. Nat Commun 12:4507. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302731/
11. Sinha R, Levin J, et al. (n-Lorem Foundation / Krainer lab) (2024). Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. Genes (Basel) 15(7):821. https://www.mdpi.com/2073-4425/15/7/821
12. NORD (National Organization for Rare Disorders). Familial Dysautonomia. https://rarediseases.org/rare-diseases/familial-dysautonomia/
13. Gregg AR, Aarabi M, Klugman S, et al. (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: an ACMG practice resource. Genet Med 23(10):1793-1806. https://pubmed.ncbi.nlm.nih.gov/34285390/
14. Richards S, Aziz N, Bale S, et al. (2015). Standards and guidelines for the interpretation of sequence variants (ACMG/AMP). Genet Med 17(5):405-424. https://pubmed.ncbi.nlm.nih.gov/25741868/
15. NHGRI / genome.gov. Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA, 2008). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
16. Supreme Court of Canada (2020). Reference re Genetic Non-Discrimination Act, 2020 SCC 17. https://www.scc-csc.ca/case-dossier/cb/2020/37676-eng.aspx

---

Last updated: 2026-08-16

Author: genelumen editorial team. This article aggregates 16 sources from peer-reviewed medical literature and public health agencies (tier 1=12 / tier 2=4), including NIH MedlinePlus, OMIM, GeneReviews (NCBI), the FDA, ACMG guidelines, NORD, and the Supreme Court of Canada.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Neurogenetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-neurogenetic/familial-dysautonomia-elp1-riley-day-inheritance-carrier-guide